Zhang M, Tang Y, Liang J, Zhu L, et al. Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase ? study. Lung Cancer 2025;205:108630.
PMID: 40555062